Ahren II

Phaidra, Inc. specializes in designing and developing artificial intelligence solutions tailored for industrial companies in the United States. Founded in 2019 and based in Seattle, Washington, the company offers AI-powered control systems that assist large industrial facilities in learning, adapting, and enhancing their performance. Phaidra's technology analyzes extensive sensor data to create intelligent AI agents capable of automatically controlling and optimizing complex industrial processes. This innovation enables clients to improve energy efficiency and sustainability, enhance plant safety and stability, and maximize operational yield.

AI21 is bringing AI into the 21st century by developing the next generation of artificial intelligence software.

Bitfount is a privacy-preserving platform that facilitates data collaboration for artificial intelligence and machine learning. It enables federated data collaborations, allowing organizations to work together without the need to share raw data. By employing federated learning and other privacy-preserving techniques, Bitfount supports the creation of data consortia, where data providers, data scientists, and governance teams can collaborate effectively. The platform aims to license and train advanced AI models while ensuring that privacy and data quality are maintained throughout the process. This approach allows for significant advancements in AI development while safeguarding sensitive information.

Heirloom is focused on developing innovative carbon capture and utilization technology to address climate change by capturing atmospheric carbon dioxide. The company utilizes a mineralization process known as enhanced weathering, which aims to remove one billion tons of carbon dioxide from the atmosphere. By deploying its Direct Air Capture solution at a gigaton scale, Heirloom facilitates the restoration of the atmosphere through natural processes, while minimizing secondary impacts and reducing extraction needs. This approach positions Heirloom as a leader in the effort to mitigate climate change through effective carbon dioxide removal strategies.

OxDX is a spinout that combines the power of single-molecule fluorescent microscopy with machine learning to identify pathogens in under a minute. They use a universal labelling system to light up everything in our sample, image the sample using super-resolution fluorescence microscopy, and analyse the images in our neural network.

Micropsi Industries GmbH is a robotics software company based in Berlin, Germany, founded in 2014. The company specializes in developing advanced machine learning solutions for robotics and process control. Its flagship product, MIRAI, is an AI-based, sensor-driven robot control system designed for complex assembly tasks. MIRAI enables robots to perform movements that adapt to subtle environmental changes detected by cameras and force sensors. Unlike traditional programming methods, MIRAI's skills are acquired through demonstration, correction, and repetition, allowing users to create robotic capabilities without needing to write code. This innovative approach enhances productivity, ergonomics, and resilience in various industrial applications. The company is supported by notable investors, including Vito Ventures and coparion, as well as experienced business angels from Munich and Berlin.

Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.

ZOE is a nutritional science company on a mission to help everybody eat with confidence. Leading the world’s largest scientific study of nutritional response.ZOE have a right to better understand our bodies, so we can make more confident decisions about food.

Adrestia is developing therapeutics that work in an entirely new way – restoring the biological balance in damaged, diseased or dying cells

Zapata Computing is a quantum software company that offers computing solutions for industrial and commercial use. It provides hardware-agnostic solutions for simulation, optimization, and machine learning applications in chemistry, finance, logistics, pharmaceuticals, engineering, and materials. Zapata Computing is a spun out of Harvard University launched by a group of Harvard scientists, including Alán Aspuru-Guzik. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

Nu Quantum Ltd is a Cambridge-based company that specializes in the development of quantum photonics hardware, including photon sources and detectors, as well as quantum cryptography systems. Founded in 2018, the company focuses on creating nano-engineered materials that facilitate light generation at the quantum level and enable ultra-sensitive light detection. It also develops fundamental algorithms and protocols for generating secure cryptographic keys and offers quantum encryption links for secure communications. By integrating novel materials and semiconductor technology, Nu Quantum aims to provide end-to-end quantum cryptography solutions that secure communications over urban and satellite free-space optical links, thereby supporting the future of information processing and quantum networking infrastructure.

Rockley Photonics Limited, founded in 2013 and headquartered in Pasadena, California, specializes in the development of silicon photonics technologies for various applications, including data communications and consumer products. The company manufactures photonic chips and custom integrated packaged products, focusing on both chipset sales and customer-specific designs. Rockley Photonics integrates its research and development efforts to create a comprehensive range of optical modules that include supporting electronics, software, application algorithms, and AI platforms. These offerings are tailored for high-volume applications across dynamic and growing market sectors, demonstrating the company's commitment to innovation in photonics technology.

Graphcore Limited, a hardware systems company develops intelligent processing units. It offers IPU-Accelerator cards, which can be plugged into a server to accelerate machine-learning applications; and IPU-Appliance products that provide enhanced performance to deliver inference systems supporting various users or provide faster training. Graphcore Limited was incorporated in 2016 and is based in Bristol, United Kingdom with additional locations in Palo Alto, California; London, United Kingdom; Oslo, Norway; and Beijing, China.

Nu Quantum Ltd is a Cambridge-based company that specializes in the development of quantum photonics hardware, including photon sources and detectors, as well as quantum cryptography systems. Founded in 2018, the company focuses on creating nano-engineered materials that facilitate light generation at the quantum level and enable ultra-sensitive light detection. It also develops fundamental algorithms and protocols for generating secure cryptographic keys and offers quantum encryption links for secure communications. By integrating novel materials and semiconductor technology, Nu Quantum aims to provide end-to-end quantum cryptography solutions that secure communications over urban and satellite free-space optical links, thereby supporting the future of information processing and quantum networking infrastructure.

Mogrify is a UK biotechnology company focused on advancing ex vivo cell therapies and developing innovative in vivo reprogramming therapies. It has created a proprietary platform that enables the direct conversion of mature cell types into other mature states without reverting to a stem cell stage, significantly improving the efficiency of stem cell-derived reprogramming. Mogrify aims to create a consistent and scalable source of cell types with the necessary efficacy and safety profiles for treating various high unmet clinical needs, particularly in oncology and ophthalmology. The company’s technology is protected by a foundational patent and additional applications that cover specific cell conversions. Mogrify employs a business model that includes internal cell therapy development, co-development partnerships, and licensing agreements for its novel cell conversions, targeting the expanding regenerative medicine market. Founded in 2016, Mogrify is headquartered in Cambridge, United Kingdom.

Mogrify is a UK biotechnology company focused on advancing ex vivo cell therapies and developing innovative in vivo reprogramming therapies. It has created a proprietary platform that enables the direct conversion of mature cell types into other mature states without reverting to a stem cell stage, significantly improving the efficiency of stem cell-derived reprogramming. Mogrify aims to create a consistent and scalable source of cell types with the necessary efficacy and safety profiles for treating various high unmet clinical needs, particularly in oncology and ophthalmology. The company’s technology is protected by a foundational patent and additional applications that cover specific cell conversions. Mogrify employs a business model that includes internal cell therapy development, co-development partnerships, and licensing agreements for its novel cell conversions, targeting the expanding regenerative medicine market. Founded in 2016, Mogrify is headquartered in Cambridge, United Kingdom.

6D.ai is a company that specializes in developing application programming interfaces (APIs) for the augmented reality (AR) industry. Founded in 2017 and headquartered in San Francisco, California, 6D.ai focuses on creating a real-time, three-dimensional semantic map of the world utilizing standard smartphone cameras and mobile sensors. Its platform constructs dense meshes from crowdsourced data, enabling 3D mapping and multi-user AR experiences. The technology operates in the background, capturing environmental data to facilitate the development of applications that interact meaningfully with the physical world. As of March 2020, 6D.ai operates as a subsidiary of Niantic, Inc.

Mogrify is a UK biotechnology company focused on advancing ex vivo cell therapies and developing innovative in vivo reprogramming therapies. It has created a proprietary platform that enables the direct conversion of mature cell types into other mature states without reverting to a stem cell stage, significantly improving the efficiency of stem cell-derived reprogramming. Mogrify aims to create a consistent and scalable source of cell types with the necessary efficacy and safety profiles for treating various high unmet clinical needs, particularly in oncology and ophthalmology. The company’s technology is protected by a foundational patent and additional applications that cover specific cell conversions. Mogrify employs a business model that includes internal cell therapy development, co-development partnerships, and licensing agreements for its novel cell conversions, targeting the expanding regenerative medicine market. Founded in 2016, Mogrify is headquartered in Cambridge, United Kingdom.

Mogrify is a UK biotechnology company focused on advancing ex vivo cell therapies and developing innovative in vivo reprogramming therapies. It has created a proprietary platform that enables the direct conversion of mature cell types into other mature states without reverting to a stem cell stage, significantly improving the efficiency of stem cell-derived reprogramming. Mogrify aims to create a consistent and scalable source of cell types with the necessary efficacy and safety profiles for treating various high unmet clinical needs, particularly in oncology and ophthalmology. The company’s technology is protected by a foundational patent and additional applications that cover specific cell conversions. Mogrify employs a business model that includes internal cell therapy development, co-development partnerships, and licensing agreements for its novel cell conversions, targeting the expanding regenerative medicine market. Founded in 2016, Mogrify is headquartered in Cambridge, United Kingdom.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

Adrestia is developing therapeutics that work in an entirely new way – restoring the biological balance in damaged, diseased or dying cells

Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.

Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.